GB0308604D0 - Pharmaceutical combinations for treating viral infections - Google Patents

Pharmaceutical combinations for treating viral infections

Info

Publication number
GB0308604D0
GB0308604D0 GBGB0308604.8A GB0308604A GB0308604D0 GB 0308604 D0 GB0308604 D0 GB 0308604D0 GB 0308604 A GB0308604 A GB 0308604A GB 0308604 D0 GB0308604 D0 GB 0308604D0
Authority
GB
United Kingdom
Prior art keywords
viral infections
treating viral
pharmaceutical combinations
pharmaceutical
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB0308604.8A
Other versions
GB2400553A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cipla Ltd
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Priority to GB0308604A priority Critical patent/GB2400553A/en
Publication of GB0308604D0 publication Critical patent/GB0308604D0/en
Priority to PCT/GB2004/001623 priority patent/WO2004089383A1/en
Priority to CL200401263A priority patent/CL2004001263A1/en
Publication of GB2400553A publication Critical patent/GB2400553A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
GB0308604A 2003-04-14 2003-04-14 Antiviral pharmaceutical combination of lamivudine, stavudine and efavirenz, or derivatives thereof Withdrawn GB2400553A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB0308604A GB2400553A (en) 2003-04-14 2003-04-14 Antiviral pharmaceutical combination of lamivudine, stavudine and efavirenz, or derivatives thereof
PCT/GB2004/001623 WO2004089383A1 (en) 2003-04-14 2004-04-14 Pharmaceutical combinations comprising lamivudine, stavudine and efavirenz for treating viral infections
CL200401263A CL2004001263A1 (en) 2003-04-14 2004-05-25 PHARMACEUTICAL COMPOSITION THAT INCLUDES LAMIVUDINE, ESTAVUDINE AND EFAVIRENZO, OR DERIVATIVES OF THEM, PHARMACEUTICAL KIT; PROCEDURE FOR PREPARATION; AND USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF VIRAL INFECTIONS,

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0308604A GB2400553A (en) 2003-04-14 2003-04-14 Antiviral pharmaceutical combination of lamivudine, stavudine and efavirenz, or derivatives thereof

Publications (2)

Publication Number Publication Date
GB0308604D0 true GB0308604D0 (en) 2003-05-21
GB2400553A GB2400553A (en) 2004-10-20

Family

ID=9956764

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0308604A Withdrawn GB2400553A (en) 2003-04-14 2003-04-14 Antiviral pharmaceutical combination of lamivudine, stavudine and efavirenz, or derivatives thereof

Country Status (3)

Country Link
CL (1) CL2004001263A1 (en)
GB (1) GB2400553A (en)
WO (1) WO2004089383A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009106960A2 (en) * 2008-02-27 2009-09-03 Aurobindo Pharma Limited Stable compositions of lamivudine, tenofovir and efavirenz
WO2022053993A2 (en) * 2020-09-12 2022-03-17 Mylan Laboratories Limited Treatments for sars-cov-2 infection (covid-19)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4970782A1 (en) * 1997-11-13 2000-11-07 Merck & Co Inc COMBINED THERAPY FOR THE TREATMENT OF AIDS
US6455548B2 (en) * 2000-02-28 2002-09-24 Merck & Co., Inc. 4-alkyl piperidinyl pyrrolidine modulators of chemokine receptor activity
US20050065319A1 (en) * 2000-12-19 2005-03-24 Baroudy Bahige M. Combination method for treating viral infections

Also Published As

Publication number Publication date
WO2004089383A1 (en) 2004-10-21
CL2004001263A1 (en) 2005-05-06
GB2400553A (en) 2004-10-20

Similar Documents

Publication Publication Date Title
IL174685A0 (en) Nucleoside compounds for treating viral infections
PL380828A1 (en) Phosphoranians, amidomonophosphoranians, amidobisphosphoranians for treating virus diseases
IL184955A0 (en) Tricyclic-nucleoside compounds for treating viral infections
PL376454A1 (en) 1-acyl-pyrrolidine derivatives for the treatment of viral infections
IL174684A0 (en) Nucleoside compounds for treating viral infections
EG27104A (en) Pharmaceutical compounds
EP1594512A4 (en) Compounds for the treatment of viral infection
IL178141A0 (en) Combinations for treating hiv infection
GB0315657D0 (en) Pharmaceutical compounds
IL173365A0 (en) Piperazine derivatives for the treatment of hiv infections
IL203061A (en) Halogenated benzamide compounds for treating viral infections
IL189792A0 (en) Benzodiazepine derivatives for treating hepatitis c infection
HK1095036A1 (en) Virus therapeutic drug
GB0308511D0 (en) Pharmaceutical compounds
GB0329254D0 (en) Treatment of viral infections
GB2411354B (en) Use of Scutellaria for the treatment of viral infections
EP1626692A4 (en) Compounds for the treatment of flaviviridae infections
EP1660116A4 (en) Method of treating viral infections
AU2003303123A8 (en) Dna vaccines against hantavirus infections
GB0317315D0 (en) Pharmaceutical compounds
GB0329958D0 (en) Treatment of viral infections
GB0313766D0 (en) Pharmaceutical compounds
GB0308603D0 (en) Pharmaceutical combinations for treating viral infections
AU2003237088A8 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
GB0301736D0 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1070814

Country of ref document: HK

WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1070814

Country of ref document: HK